HopeStage
Back to all studies
CompletedNCT01863459

Lisdexamfetamine for Adult ADHD With Anxiety or Depression

About this titleRead the official source — NCT01863459
Medication studyAges 18–65Canada
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
HamiltonSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateApril 2013
Recruitment status
Completed
Enrollment listed in the registry
42
Sponsor
Centre for Anxiety, Attention Deficit and Trauma, Ontario, Canada
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Canada
Age range
From 18 Years to 65 Years
Official registry ID
NCT01863459
Official title
Show the full official title

Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Hamilton

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Centre for Anxiety, Attention Deficit and Trauma, Ontario, Canada.

Did this study involve medication?

Yes. The study involved medication, including Lisdexamfetamine Dimesylate and placebo.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies